Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Completed · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

* Multi-Center * Randomized * Open-Label Study of single agent IMO-2055 * Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

Key facts

Study ID

NCT00729053

Run by

Idera Pharmaceuticals, Inc.

People needed

92

Starts

2004-06-01

Expected to finish

2008-11-01

Last updated by the study team

2018-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed stage IV clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable.
• At least one measurable lesion
• Adequate organ function
• Any prior treatment of renal cell cancer was concluded at least 4 weeks prior.
• If female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug.

You may not qualify if…

• Known untreated central nervous system (CNS) metastasis
• Pre-existing autoimmune or antibody-mediated diseases
• Other significant medical disease.

Where it is running

• Georgetown University, Lombardi Cancer Center — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.